2091.8000 -9.30 (-0.44%)
NSE Apr 02, 2026 15:31 PM
Volume: 970.1K
 

2091.80
-0.44%
Deven Choksey
We have revised our FY26E/FY27E EPS estimates by -1.1 %/+13.2%, respectively, as we factor in improvement in EBITDA margins on account of improving mix and launch of high margin products.
Glenmark Pharmaceuti.. has an average target of 2121.50 from 4 brokers.
More from Glenmark Pharmaceuticals Ltd.
Recommended